<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirteen patients with low-to-intermediate risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) received recombinant erythropoietin (r-EPO) at the single, weekly dose of 40.000 U for at least 8 weeks </plain></SENT>
<SENT sid="1" pm="."><plain>Five patients (38.4%) achieved a major erythroid response (increased <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> levels &gt; 2 g/dl and/or transfusion independence), which is currently maintained after 3-11 months, without modification of r-EPO dose </plain></SENT>
<SENT sid="2" pm="."><plain>This study suggests that 40.000 U r-EPO given once a week may be at least as effective as the more frequent (daily or three times a week) administrations of the drug usually employed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>